# 22nd Annual Conference of the British HIV Association (BHIVA)

## Dr. Alessia Dalla Pria
Chelsea and Westminster Hospital

<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker Name</td>
<td>Declaration</td>
</tr>
<tr>
<td></td>
<td>None</td>
</tr>
</tbody>
</table>

| Date | April 2016 |
Relapse of Multicentric Castleman`s disease (MCD) following Rituximab based therapy in 82 PLWH

Dr. Alessia Dalla Pria
National Centre for HIV malignancies
Chelsea & Westminster Hospital
### HIV associated MCD

<table>
<thead>
<tr>
<th>Localised</th>
<th>Hyaline vascular</th>
<th>Plasmablastic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multicentric</td>
<td></td>
<td>HIV-MCD</td>
</tr>
</tbody>
</table>
Plasmablasts infected by KSHV

KSHV LANA-1 staining
Dr. Benjamin Castleman (1906 - 1982)

Prof. Mark Bower
How do we now treat MCD?

- **PS 0-1, No end organ damage**
  - Rituximab

- **PS ≥2, end organ damage**
  - Etoposide & Rituximab
Survival pre Rituximab era

5 year overall survival 33% (95% CI: 6-60%)

Median survival 4 m

cf: (Oksenhendler et al 1996)
Largest published series
n=20
Median survival 14 m
Survival Rituximab era

Median follow up 4.2 years

$n = 98$

5 year overall survival 95% (CI: 90-100%)
98 PLWH & MCD

Median HHV8 350,000 cp/mL

82 Rx Rituximab +/- E

78 in remission

4 died of MCD progression

5 died of varying causes

11 relapsed
78 in remission

Median time to relapse 19 months (8.7-49)

11 relapsed

R = 8

5 2nd relapse

R+E = 3

3 3rd relapse

Median CD 19 (B-cell) at relapse 204 (16%)

Median HHV8 at relapse 130.000 cp/mL

1 4th relapse (died)
Survival from first relapse
Conclusions

Relapse following Rituximab based treatment for MCD is not infrequent and may occur after recovery of CD 19 (B-cell) counts.

Relapses are usually sensitive to rechallenging with Rituximab based immunochemotherapy.
Thank you

- Prof Mark Bower
- Prof Mark Nelson
- Dr Sarah Chitty
- Dr Ramya Ramaswami
- Miss Shauna McCann
- Miss Kizzy Parker

- ALL OUR PATIENTS!